ArtemisShield Animal Health Co., Ltd. is the holding company of Kexing Biopharm Co., Ltd. Kexing Biopharm (stock code: 688136) is an innovative biopharmaceutical enterprise mainly engaged in the integration of R&D, production and sales of recombinant protein drugs and microecological preparations. It focuses on antiviral, tumor and immune, blood, digestion, degenerative diseases and other therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of "innovation+ internationalization", At the same time, it explores the extensive application of biotechnology in the field of general health, actively cultivates and incubates new industries, the world's leading industrial platforms such as animal vaccines, synthetic organisms have been distributed，and is committed to becoming a leader in high-quality biopharmaceutics and serving global patients.

With over 20 years of experience in independent innovation and successful industrialization of a wide range of products, Kexing Biopharm has demonstrated robust capabilities in large-scale production of biological macromolecules, microecological preparations, and high-end complex preparations. The company's production capabilities include 60 million vials/year of recombinant protein lyophilized injections, 50 million vials/year of genetic engineering injections, 300 million bags/year of microecological oral preparations, 72 million capsules/year of traditional Chinese medicine oral preparations, and 2 million vials/year of high-end complex injections.

In recent years, Kexing Biopharm has experienced continued and rapid growth and served as an industry leader in the field of recombinant protein therapeutics. The company's core products outperform competitors' options and are supplied to over 20,000 terminals across China, including approximately 7,000 different grades of hospitals. Kexing Biopharm, with over two decades of experience in the overseas commercialization of biological drugs, has acquired market access and achieved sales in over 40 countries and regions globally，including Brazil, the Philippines, and Indonesia. Looking ahead, we plan to further expand our international footprint by establishing seven overseas subsidiaries or offices in seven different countries and regions around the globe.